Autologous matrix-induced chondrogenesis a biological treatment option for localized full-thickness cartilage defects combining with microfracture surgery with the application of a bi-layer collagen I/III membrane. Autologous matrix-induced chondrogenesis is a recent technique, and hence does not have extensive clinical data. This is restraining physicians/doctors from adopting autologous matrix-induced chondrogenesis methods for treating patients suffering from bone and joint disorders.
The global Autologous Matrix-Induced Chondrogenesis Market was valued at US$ 89.7 Mn in 2015 and is expected to grow at a CAGR of 8.6% during the forecast period from 2016 to 2024 to reach US$ 186.4 Mn in 2024
The global autologous matrix-induced chondrogenesis market is divided into two segments: by material and by geography. Based on the material the market has segmented into hyaluronic acid, collagen, polyethylene glycol (PEG), poly lactic-co-glycolic acid (PGLA) and others segment. Between these segments, collagen accounted for largest share of the autologous matrix-induced chondrogenesis market in 2015 (in terms of revenue) followed by hyaluronic acid. Collagen accounts for approximately 30% of all protein within the human body and has been used extensively for tissue engineering applications.
Most of the countries have less or no reimbursement for autologous matrix-induced chondrogenesis products or procedures. Autologous matrix-induced chondrogenesis products or procedures are not reimbursed by several health insurance companies in Europe. There is no reimbursement in most of the developing countries such as India, Australia, and Brazil. Hence, lack of efficient reimbursement is likely to hamper the growth of the autologous matrix-induced chondrogenesis market during the forecast period.
Geographically, the autologous matrix-induced chondrogenesis market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the autologous matrix-induced chondrogenesis market in 2015, followed by Europe. Increasing geriatric population and increasing demand for minimal invasive procedures are likely to drive the growth of the market in the forecast period. According to the Centers for Disease Control and Prevention, an estimated 67 million people in the U.S. above 18 years of age would be diagnosed with arthritis by 2030. Moreover, arthritis is considered a leading cause of disability among the global population and results in reconstructive bone and joint surgery.
Get a Sample Copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19289
In Europe, Germany and France accounted more than 45% share of the total Europe autologous matrix-induced chondrogenesis market in 2015. Europe is expected to increase during the forecast period due to technological advancements, launch of new products, such as Geistlich Bio-Gide Compressed and minimal invasive nature of autologous matrix-induced chondrogenesis compared to other biological procedures. According to the European Injury Data Base catalogue of sports, annually, about 4.5 million people aged 15 years and above have to be treated in hospital for sports injury. When children under the age of 15 are included, the estimate is 5.8 million sports injuries annually.
Asia Pacific is the most attractive market and expected to increase at the highest CAGR in the forecast period due to due to entry of western companies and increasing adoption of new technologies and cost effective nature of autologous matrix-induced chondrogenesis compared to other biological procedures. Rise in geriatric population is expected to boost the growth of the autologous matrix-induced chondrogenesis market in the region. According to the Government of Japan, the country has the fastest growing geriatric population that reached a record of 31.86 million in September 2013. The geriatric population is expected to reach 95.2 million by 2050.
Latin America autologous matrix-induced chondrogenesis market is expected to grow in the forecast period due to increasing geriatric population. According to the World Health Organization, Brazil’s geriatric population stood at 14 million in 2015, or just under 8% of the total population of 195 million. It is forecast to reach 49 million by 2050, a 300% increase.
The global autologous matrix-induced chondrogenesis market is consolidated in which relatively small number of companies accounted for majority market share. Major players operating in the global autologous matrix-induced chondrogenesis market are Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc and Zimmer Biomet Holdings.
The global autologous matrix-induced chondrogenesis market is segmented as follows:
Global Autologous Matrix-Induced Chondrogenesis Market, by Material
- Hyaluronic Acid
- Polyethylene Glycol (PEG)
- Poly lactic-co-glycolic acid (PGLA
Global Autologous Matrix-Induced Chondrogenesis Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453